Lv47
538 积分 2026-04-08 加入
Anlotinib improves bile duct ligature‐induced liver fibrosis in rats via antiangiogenesis regulated by VEGFR2/mTOR pathway
9天前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
14天前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
16天前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
17天前
已完结
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression
18天前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
25天前
已完结
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
25天前
已完结
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
1个月前
已完结
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
1个月前
已完结
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
1个月前
已完结
皖公网安备34019202002308
